Investor skepticism is growing over the timeline for returns from AI in drug discovery, creating a disconnect with Wall Street's expectations. [1, 5] While AI has shown promise in accelerating the early stages of identifying drug candidates, it has not yet altered the fundamental 10- to 15-year timeline required for clinical trials and regulatory approval. [8, 10] This extended horizon conflicts with the market's demand for near-term results, causing pressure on valuations for companies in the sector. [1]
After a period of significant investment, 2026 is emerging as a critical "prove it" year, with investors shifting focus from technological promise to the need for concrete clinical validation. [7] Several AI-designed drug candidates have faced setbacks in trials, highlighting that faster discovery does not yet guarantee a higher rate of success in later stages. [12, 14] Consequently, the industry is seeing a recalibration of expectations as the complexities of biology and regulation temper the initial hype. [7]